CLINICAL TRIALS PROFILE FOR STRATTERA

All Clinical Trials for STRATTERA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00174226 ↗	Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar	Completed	Pfizer	Phase 2	2004-11-01	Determine if there is a difference in treatment response for adults with ADHD who are treated with Strattera versus those treated with a combination of Strattera and buspirone
NCT00181766 ↗	Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)	Completed	Eli Lilly and Company	Phase 4	2003-12-01	This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the treatment of adults with attention deficit hyperactivity disorder not otherwise specified. The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day, whichever is less) in adults with ADHD NOS will be safe and well tolerated.
NCT00181766 ↗	Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)	Completed	Massachusetts General Hospital	Phase 4	2003-12-01	This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the treatment of adults with attention deficit hyperactivity disorder not otherwise specified. The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day, whichever is less) in adults with ADHD NOS will be safe and well tolerated.
NCT00181948 ↗	Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy	Completed	Eli Lilly and Company	Phase 4	2004-09-01	This will be a 6-week, unblinded study using the medication Strattera for children and adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an adequate trial of stimulant treatment. Specific hypotheses are as follows: Hypothesis 1: ADHD symptomatology in youth with ADHD will be responsive to Strattera treatment in the short term. Hypothesis 2: Strattera treatment (in doses of up to 120 mg/day or 1.2 mg/kg/day) in children and adolescents with ADHD will be safe and well tolerated.
NCT00181948 ↗	Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy	Completed	Massachusetts General Hospital	Phase 4	2004-09-01	This will be a 6-week, unblinded study using the medication Strattera for children and adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an adequate trial of stimulant treatment. Specific hypotheses are as follows: Hypothesis 1: ADHD symptomatology in youth with ADHD will be responsive to Strattera treatment in the short term. Hypothesis 2: Strattera treatment (in doses of up to 120 mg/day or 1.2 mg/kg/day) in children and adolescents with ADHD will be safe and well tolerated.
NCT00190684 ↗	Long-Term, Open Label Atomoxetine Study	Completed	Eli Lilly and Company	Phase 3	2000-08-01	To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for about 5 years (long-term). Study participants can be atomoxetine naive, atomoxetine experienced whose therapy has been interrupted or, atomoxetine experienced on a known stable dose.
NCT00190775 ↗	A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)	Completed	Eli Lilly and Company	Phase 4	2004-09-01	This is a parallel design, double-blind, placebo-controlled, multi-center, 38-week treatment trial of atomoxetine in adults with attention deficit hyperactivity disorder (ADHD) who are currently living in a family situation with at least one child. The primary objective of the study is to demonstrate the efficacy of atomoxetine compared to placebo in the reduction of ADHD symptoms over 12 and 24 weeks of blinded treatment.

Clinical Trial Conditions for STRATTERA

Condition Name

Condition Name for STRATTERA
Intervention	Trials
Attention Deficit Hyperactivity Disorder	35
Attention Deficit Disorder With Hyperactivity	7
ADHD	5
Attention Deficit Hyperactivity Disorder (ADHD)	4

Condition MeSH

Condition MeSH for STRATTERA
Intervention	Trials
Attention Deficit Disorder with Hyperactivity	54
Hyperkinesis	42
Disease	34
Cognition Disorders	4

Clinical Trial Locations for STRATTERA

Trials by Country

Trials by Country for STRATTERA
Location	Trials
United States	175
United Kingdom	22
Spain	16
Canada	12
Germany	12

Trials by US State

Trials by US State for STRATTERA
Location	Trials
New York	11
California	8
Tennessee	8
Ohio	8
Massachusetts	8

Clinical Trial Progress for STRATTERA

Clinical Trial Phase

Clinical Trial Phase for STRATTERA
Clinical Trial Phase	Trials
Phase 4	29
Phase 3	16
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for STRATTERA
Clinical Trial Phase	Trials
Completed	72
Terminated	6
Unknown status	6

Clinical Trial Sponsors for STRATTERA

Sponsor Name

Sponsor Name for STRATTERA
Sponsor	Trials
Eli Lilly and Company	35
National Institute of Mental Health (NIMH)	6
National Institute on Drug Abuse (NIDA)	6

Sponsor Type

Sponsor Type for STRATTERA
Sponsor	Trials
Other	82
Industry	46
NIH	21